ATOMIC Energy — Biomarker-Bespoke Adjuvant Therapy for Colon Cancer
Mené sur 712 patients atteints d'un cancer du côlon de stade III présentant une déficience du système MMR (âge médian : 64 ans ; durée médiane de suivi : 40,9 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'ajout d'atézolizumab à un traitement de type mFOLFOX6
In countries with organized screening programs for colorectal cancer, 25% of patients who receive a diagnosis have stage III disease with involved regional lymph nodes. Surgery cures only half these patients, and 6 months of fluoropyrimidine-based adjuvant chemotherapy (e.g., intravenous fluorouracil or oral capecitabine) has been the cornerstone of treatment since 1990 because it reduces the risks of recurrence and death. Given that 1.9 million new diagnoses of colorectal cancer are expected in 2026,1 optimizing adjuvant therapy is a priority. Mismatch repair–deficient (dMMR) tumors, which lack the ability to fix errors arising during DNA replication, account for 10 to 15% . . .
New England Journal of Medicine , éditorial, 2026